Related Experiment Videos
Targeting p53 as a general tumor antigen
M Theobald1, J Biggs, D Dittmer
1Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, USA.
Abstract:
A major barrier to the design of immunotherapeutics and vaccines for cancer is the idiosyncratic nature of many tumor antigens and the possibility that T cells may be tolerant of broadly distributed antigens. We have devised an experimental strategy that exploits species differences in protein sequences to circumvent tolerance of high-affinity T cells. HLA transgenic mice were used to obtain cytotoxic T lymphocytes specific for peptides from the human p53 tumor-suppressor molecule presented in association with HLA-A2.1. Although such p53-specific cytotoxic T cells did not recognize nontransformed human cells, they were able to lyse a wide variety of human tumor cells lines, thus confirming the existence of broadly distributed determinants that may serve as targets for immunotherapy.
Insights
Researchers bypassed T cell tolerance to cancer antigens by using species differences. This strategy identified broadly distributed tumor targets for effective cancer immunotherapy and vaccines.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cancer immunotherapy and vaccine design face challenges due to unique tumor antigens and T cell tolerance.
- Developing therapies that target broadly distributed tumor antigens is crucial for effective cancer treatment.
Purpose of the Study:
- To devise a strategy to overcome T cell tolerance to tumor antigens.
- To identify broadly distributed tumor determinants for immunotherapy.
Main Methods:
- Utilized HLA transgenic mice to generate cytotoxic T lymphocytes.
- Focused on peptides from the human p53 tumor-suppressor molecule presented by HLA-A2.1.
- Exploited species differences in protein sequences to circumvent T cell tolerance.
Main Results:
- Generated p53-specific cytotoxic T lymphocytes.
- These T cells did not recognize normal human cells.
- Demonstrated lysis of diverse human tumor cell lines by the generated T cells.
Conclusions:
- Confirmed the existence of broadly distributed tumor determinants.
- These determinants can serve as targets for novel cancer immunotherapies and vaccines.
- The experimental strategy effectively circumvents T cell tolerance to high-affinity T cells.